Purpose To assess current antithrombotic treatment strategies in the Netherlands in patients undergoing transcatheter aortic valve implantation (TAVI). Methods For every Dutch hospital performing TAVI (n =14) an interventional cardiologist experienced in performing TAVI was interviewed concerning heparin, aspirin, thienopyridine and oral anticoagulation treatment in patients undergoing TAVI. Results The response rate was 100 %. In every centre, a protocol for antithrombotic treatment after TAVI was available. Aspirin was prescribed in all centres, concomitant clopidogrel was prescribed 13 of the 14 centres. Duration of concomitant clopidogrel was 3 months in over twothirds of cases. In 2 centres, duration of concomitant clopidogrel was based upon type of prosthesis: 6 months versus 3 months for supra-annular and intra-annular prostheses, respectively. Conclusions Leaning on a small basis of evidence and recommendations, the antithrombotic policy for patients undergoing TAVI is highly variable in the Netherlands. As a standardised regimen might further reduce haemorrhagic complications, large randomised clinical trials may help to establish the most appropriate approach.

Aspirin, Bleeding, Clopidogrel, Dual antiplatelet therapy (DAPT), Thrombosis, Transcatheter aorticvalve implantation (TAVI)
dx.doi.org/10.1007/s12471-013-0496-6, hdl.handle.net/1765/68008
Netherlands Heart Journal
Department of Otorhinolaryngology

Nijenhuis, V.J, Stella, P.R, Baan, J, Jr., Brueren, B.R.G, de Jaegere, P.P.T, den Heijer, P, … ten Berg, J.M. (2014). Antithrombotic therapy in patients undergoing TAVI: An overview of Dutch hospitals. Netherlands Heart Journal, 22(2), 64–69. doi:10.1007/s12471-013-0496-6